News
12hon MSN
A population-based cohort study emulating a target trial estimated the effect of glucagon-like peptide-1 receptor agonists ...
The Europe GLP-1 agonists market, valued at USD 7.09 billion in 2024, is set to grow at a 17.30% CAGR, reaching USD 14.34 billion by 2034. Driven by ...
Men were three times more likely than women to say GLP-1s boosted their confidence and two times more likely to say they were going on more dates. They also reported higher libido, more matches and ...
10h
HealthDay on MSNCertain Factors May Predict Weight Fluctuations After GLP-1 Receptor Agonist TreatmentFor adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 ...
Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...
People who use GLP-1 weight loss drugs like Ozempic are more likely to suffer from severe acid reflux, or GERD, a new ...
Adrenal adenomas were associated with attenuated weight loss among patients with obesity or overweight using GLP-1 or GIP/GLP ...
In this cohort study, the use of glucagon-like peptide 1 receptor agonists (GLP-1RAs) semaglutide and tirzepatide was associated with ...
A new study finds four factors that may make it more likely for some people to experience successful weight loss from using ...
New Phase II data presented at ENDO 2025 highlight avexitide’s potential to significantly reduce severe hypoglycemic events ...
GLP-1 receptor agonists such as semaglutide and liraglutide promote significant weight loss and improved glycemic control, ...
A study in Diabetes, Obesity and Metabolism has identified certain characteristics that might influence people's weight loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results